#EAPM: Daugialypės terpės dalyviai susirenka Madride, siekdami paskatinti geresnę pacientų prieigą

The European Hematology Association (EHA) will hold its 22nd annual congress from Thursday (22 June) of this week in an event which runs until Sunday, rašo Europos aljansas už Pritaikomo Medicina (EAPM) vykdomasis direktorius Denisas Horgan.

Taking place in the Spanish capital of Madrid, this prestigious Congress is expected to attract some 15,000 delegates and speakers. It will feature a full scientific programme, alongside updates in hematology, a commercial exhibition and satellite symposia.

The Brussels-Based European Alliance for Personalised Medicine will be holding its own round table meeting on Thursday, 22 June at the Congress, entitled ‘EU options for improving access to medicines’. This is the third such event that EAPM will have hosted at the Congress, which brings together the hematology community.

Aljanso darbo grupė prieigos klausimais reguliariai aptarė tokius klausimus kaip ES problema dėl neteisingos prieigos, taip pat poreikis teikti paskatas ir tai, kas tiksliai yra "vertė" šioje srityje.

With Brexit talks having just begun, and direct European Parliamentary elections due in just two years, EAPM argues that, in the realm of health care, member states need ‘more Europe, not less’. It is true, however, that achieving this ideal is made more difficult by the fact that health is a member state competence and cooperation between the current 28 countries is sub-optimal.

It certainly won’t be helped by the UK leaving the bloc, (probably) in less than two years.

But Europe’s health-care stakeholders remain busy and, in the wake of a European Parliament re-port on the topic of improving access, the meeting in Madrid is designed to elicit responses from the healthcare community in order to understand the way they envisage moving forward.

reklama

EAPM believes that among the areas that have to come under scrutiny are the need to re-organize how modern health care works - by using all stakeholders, also a long-hard look at the regulatory balance is required, and systems need to be put in place to support innovation (including incentives). Broadly agreed and implemented incentives in order to facilitate the development of treatment are crucial, the Alliance says.

EAPM has often noted that, across the EU, the huge imbalance in access is not only on a country-by-country basis, but often occurs between regions of the same member state.

Of course, there are many reasons to explain why patient access to the right treatment at the right time is being delayed, blocked and made inequitable. And the Alliance has maintained that, while no single stakeholder is to blame, every stakeholder has a responsibility to address the situation.

Among those stakeholders speaking at the Alliance forum will be EHA secretary-general Carin Smand, and the European Parliament rapporteur on access, Soledad Cabezon Ruiz, of the Group of the Progressive Alliance of Socialists and Democrats.

The parliamentarian has said: “Some of the most serious problems are the shortages of essential medicines both outside and within the EU; the fact that the research priorities are profit-oriented rather than patient-oriented; and the high cost of ‘innovative’ medicines, which, paradoxically, for the most part fail to produce a real added value and are in fact merely modifications of molecules that already exist."

She will be joined by, among others, EAPM executive director Denis Horgan, the European Commission’s Karim Berkouk, Natacha Bolanos, of the Spanish Group for Cancer Patients, Teresa Chavarria Gimenez, of the Madrid Health Ministry, and Ivo Gut, of the Centro Nacional d'Analisi Genomica.

Generally speaking, it is clear that personalised medicine approaches have already been particularly effective in certain cancers, and have brought practice-changing clinical benefits to patients. However, spiralling costs have highlighted the need to address the cost-value dilemma, among other important issues.

The Alliance believes that there is a need to move beyond a simplistic ‘what the market can bear' approach to a more nuanced value-based pricing philosophy to allow the benefits of a value-centred strategy to accrue for patients and society in general.

This is just one aspect, and solutions to all issues need to be found via agreement at high-level that involves cross-border stakeholders, including health-care systems, as no single country can solve the issues alone.

Cabezon Ruiz meanwhile, has said: “All the member states and EU institutions, as well as the private sector directly involved, should be aware of the role they have to play.”

EAPM’s round table meeting in Madrid aims to push the agenda, and will attempt to reach consensus while making solid, achievable recommendations to the European Parliament and Commission.

To see the agenda, click here.

Pasidalinkite šiuo straipsniu: